Colin Love
Founder presso REPLIMUNE GROUP, INC.
Patrimonio netto: 6 M $ in data 31/03/2024
Provenienza dei contatti di primo grado di Colin Love
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 27 | |
| Subsidiary | Biotechnology | 21 | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.
15
| Subsidiary | Biotechnology | 15 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom.
5
| Private Company | Pharmaceuticals: Major | 5 |
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The private company is based in Abingdon, UK and was founded in 2015.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Colin Love tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Administrative Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Investor Relations Contact Comptroller/Controller/Auditor | |
| SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
| KIORA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Doctorate Degree | |
| Imperial College London | College/University | Doctorate Degree Graduate Degree | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MERRIMACK PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director of Finance/CFO Chairman Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| Yale University | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
| University of Massachusetts | College/University | Undergraduate Degree Undergraduate Degree | |
| Georgetown University | College/University | Undergraduate Degree Undergraduate Degree | |
| MEDIAN TECHNOLOGIES | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder | |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Director/Board Member Chairman | |
| UNIQURE N.V. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| JUNO THERAPEUTICS INC | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Tufts University School of Medicine | College/University | Graduate Degree Doctorate Degree | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| MORPHIC HOLDING, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Director/Board Member Chief Executive Officer | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Chairman Director/Board Member | |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Founder Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Oxyrane, Ltd. | Chairman Director/Board Member | ||
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 31 |
| Regno Unito | 9 |
| Paesi Bassi | 6 |
| Francia | 4 |
| Germania | 3 |
Settori
| Health Technology | 30 |
| Consumer Services | 11 |
| Commercial Services | 5 |
| Finance | 5 |
| Health Services | 3 |
Posizioni
| Director/Board Member | 369 |
| Corporate Officer/Principal | 147 |
| Independent Dir/Board Member | 87 |
| Chief Tech/Sci/R&D Officer | 54 |
| Undergraduate Degree | 47 |
Contatti più connessi
| Insiders | |
|---|---|
| Somu Subramaniam | 48 |
| Kapil Dhingra | 39 |
| Otello Stampacchia | 37 |
| Hugo Slootweg | 34 |
| Dieter Weinand | 32 |
| Stephen T. Reeders | 30 |
| Mounia Chaoui-Roulleau | 27 |
| Leonard Post | 25 |
| Ricky Sun | 24 |
| Jason Rhodes | 24 |
| Brett Zbar | 23 |
| Julia Gregory | 22 |
| Chris Hollowood | 19 |
| Hyam Levitsky | 18 |
| Joseph Slattery | 18 |
- Borsa valori
- Insiders
- Colin Love
- Connessioni Società
